Key result
Transapical transcatheter aortic valve replacement in extreme-risk patients resulted in a 20% hospital mortality rate and a 54% overall survival rate at 2 years.
Why the study?
Does transapical TAVR provide acceptable survival and clinical outcomes in extreme-risk patients with logistic EuroSCORE > 35%?
Population
40 'extreme-risk' patients with logistic EuroSCORE above 35%, mean age 81 ± 10 years.
Design
Cohort
Follow-up
mean 24 months
Authors
Loading...
High periprocedural mortality warrants caution for transapical TAVR in extreme-risk patients; leaves open net benefit versus medical management.
Cohort (n=40)
Does transapical TAVR provide acceptable survival and clinical outcomes in extreme-risk patients with logistic EuroSCORE > 35%?
Transapical TAVR in extreme-risk patients (EuroSCORE >35%) carries a 20% hospital mortality risk, but survivors demonstrate acceptable mid-term survival and good clinical condition without heart failure rehospitalizations.
Ferrari et al. (2012) conducted a cohort in Extreme-risk aortic valve disease (n=40). Transapical transcatheter aortic valve replacement (TA-TAVR) was evaluated on Hospital mortality. Transapical transcatheter aortic valve replacement in extreme-risk patients resulted in a 20% hospital mortality rate and a 54% overall survival rate at 2 years.